Sapna Patel, DO
Endocrinology, Diabetes & Metabolism · San Antonio, TXNPI 1508286527
Payments from drug & device makers
Across 331 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Dexcom, Inc.$841
- Corcept Therapeutics$535
- Tandem Diabetes Care, Inc.$491
- Amgen$480
- Novo Nordisk$472
- plus $4K from 36 others
What the payments were for
- Food & beverage$8,238100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 54 | $1,091 |
| Dexcom, Inc. | 21 | $841 |
| Corcept Therapeutics | 18 | $535 |
| Tandem Diabetes Care, Inc. | 14 | $491 |
| Amgen | 27 | $480 |
| Novo Nordisk | 21 | $472 |
| Abbott | 15 | $430 |
| Cequr Corporation | 3 | $368 |
| Insulet Corporation | 7 | $325 |
| Boehringer Ingelheim | 14 | $309 |
| Sanofi-aventis U.S. LLC | 10 | $305 |
| Radius Health, Inc. | 15 | $298 |
| Bayer | 12 | $202 |
| Xeris Pharmaceuticals, Inc. | 11 | $177 |
| Intuity Medical Inc | 10 | $149 |
| Mannkind Corporation | 6 | $135 |
| BETA Bionics, Inc. | 2 | $134 |
| Novartis | 7 | $131 |
| GSK | 1 | $121 |
| AbbVie | 7 | $113 |
| Kyowa Kirin, Inc. | 5 | $109 |
| Medtronic(2 entities) | 6 | $108 |
| Recordati_rare_diseases_inc. | 5 | $99 |
| Ascendis Pharma Endocrinology Inc | 4 | $91 |
| Ascensia Diabetes Care US Inc. | 3 | $79 |
| Acella Pharmaceuticals, LLC | 4 | $72 |
| Tolmar, Inc. | 4 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $59 |
| Soleno Therapeutics, Inc. | 2 | $58 |
| Chiesi USA, Inc. | 2 | $49 |
| Amneal Pharmaceuticals LLC | 3 | $46 |
| Acerus Pharmaceuticals Corporation | 2 | $41 |
| Amphastar Pharmaceuticals, Inc. | 2 | $35 |
| AstraZeneca | 2 | $34 |
| Antares Pharma, Inc. | 2 | $33 |
| Gilead | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $26 |
| Pfizer | 1 | $24 |
| Sandoz | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $20 |
| IBSA Pharma Inc. | 1 | $16 |
| RGH Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,238 in reported general payments places this provider in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 249 | $327,057 |
| MounjaroTirzepatide | 152 | $209,383 |
| TrulicityDulaglutide | 80 | $110,020 |
| ProliaDenosumab | 59 | $102,667 |
| JardianceEmpagliflozin | 59 | $88,342 |
| RybelsusSemaglutide | 54 | $66,923 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 74 | $61,102 |
| Tresiba Flextouch U-100Insulin Degludec | 72 | $51,196 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $50,403 |
| JanuviaSitagliptin Phosphate | 31 | $34,761 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $29,441 |
| FarxigaDapagliflozin Propanediol | 17 | $13,181 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $12,047 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $11,642 |
| Novolog FlexpenInsulin Aspart | 43 | $9,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $472 | $399,366322 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,091 | $321,666244 claims |
| AmgenProlia | $480 | $102,66759 claims |
| Boehringer IngelheimJardiance | $309 | $88,34259 claims |
| AstraZenecaFarxiga | $34 | $13,18117 claims |
| AbbVieSynthroid, Armour Thyroid | $113 | $10,157152 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $46 | $4,781432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in San Antonio
- Mark KipnesSan Antonio$10.3M
- Ralph DefronzoSan Antonio$4.8M
- Eugenio CersosimoSan Antonio$4M
- Devjit TripathySan Antonio$1.5M
- Carolina Solis-HerreraSan Antonio$1.3M
- Firas AkhrassSan Antonio$900K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.